Your browser is no longer supported. Please, upgrade your browser.
Settings
FBT First Trust NYSE Arca Biotech ETF daily Stock Chart
FBT [NYSE]
First Trust NYSE Arca Biotech ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-1.11%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month3.34%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter5.29%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y2.50%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-1.08%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range76.11 - 103.93 Perf YTD5.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.63% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low26.13% ATR2.05
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.30 Volatility2.47% 1.96%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.81 Prev Close95.87
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume88.42K Price96.00
Recom- SMA201.91% SMA501.45% SMA2001.52% Volume71,288 Change0.14%
Jan-16-17 10:55AM  Fidelity Biotech Fund: Better than the Index? at Motley Fool
Jan-10-17 06:24AM  Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 at Motley Fool
Dec-29-16 09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
Dec-06-16 11:57AM  Why TherapeuticsMD Inc. Jumped Today at Motley Fool
Dec-05-16 09:23AM  Is This Why Sarepta Therapeutics Fell 14.5% in November? at Motley Fool
Dec-01-16 11:04AM  How Could Gilead Sciences Restore Its Growth?
09:25AM  Why Neurocrine Biosciences May See Higher Losses in 2016
Nov-14-16 10:57AM  5 Reasons to Buy 5 Low P/E Biotech ETFs
Nov-09-16 02:52PM  Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today at Motley Fool +9.29%
01:04PM  What Drove Regenerons 3Q16 Performance?
Nov-08-16 05:49PM  Why Did Halozyme Therapeutics, Inc. Plunge 29.5% in October? at Motley Fool
03:26PM  Biotech ETFs Slumping on Q3 Results
Nov-02-16 10:05AM  Strensiq: A Potential Driver for Alexion
Oct-27-16 08:34AM  Once Beloved Momentum ETF Loses Its Momo
Oct-20-16 01:57PM  Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
08:06AM  What Are the Drivers behind the Success of Soliris?
Oct-19-16 10:05AM  Why Europe Is an Important Market for Vertexs Orkambi
Sep-29-16 12:04PM  How Regeneron Is Working to Maintain Eyleas Dominance
Sep-27-16 04:05PM  BioMarin to Cross $1 Billion Revenue in 2016
Sep-26-16 07:04PM  Higher Discontinuations Are among Orkambis Concerns
Sep-20-16 02:49PM  How Ionis Pharmaceuticals Valuation Compares to Its Peers
Sep-19-16 02:08PM  Sarepta Stock Surge Boosts Some Biotech ETFs But Not Others at Barrons.com
Sep-14-16 02:19PM  Inside the Recent Surge in Biotech ETFs
Sep-06-16 10:43AM  Technicals, Politics Clash for Biotech ETFs
Sep-05-16 10:04AM  How Is Incytes Only FDA-Approved Drug Performing?
Sep-02-16 10:49AM  Clinton's Proposal To Combat Drug Price Hikes
Aug-31-16 03:39PM  Biotech ETF Industry Outlook
10:58AM  Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns
10:05AM  United Therapeutics Makes Novel Technologies a Priority
Aug-30-16 09:39AM  Biotech ETFs Back In The Spotlight
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
Aug-25-16 01:04PM  Whats BioMarins Expected Revenue Growth in 2016 and 2017?
Aug-24-16 05:29PM  Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan (MYL) Stock?
09:04AM  How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Aug-16-16 11:30AM  Another Endorsement for Biotech ETFs
Aug-04-16 07:15AM  Biotech Breakout: Take 3
Aug-02-16 05:23PM  Big Biotech Buyout Banter Buoys IBB at Barrons.com
11:06AM  How Much Will BioMarins Kuvan Fetch in 2Q16?
Jul-25-16 11:05AM  Whats behind the Recent Fall in Alexions Valuation Multiple?
Jul-22-16 01:16PM  How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16?
01:16PM  How Can Alexion Stay ahead of the Competition with Soliris?
Jul-14-16 09:05AM  ALNY Should Complete Revusirans Endeavour Trial Enrollment in Late 2016
Jul-13-16 09:00AM  Biotech ETFs: Will the Once Hot Group Rebound?
Jul-08-16 09:25PM  Inside Alnylam Pharmaceuticalss Analyst Recommendations in 2016
03:03PM  Regeneron in 2Q16: How Much Revenue Growth Could It Have?
Jul-06-16 02:06PM  Inside BioMarins Big Plans for 3Q16
Jun-30-16 06:33PM  Biotechs Building Base?...Or Bursting Bubble?
Jun-29-16 02:24PM  BioMarins Guidance for 2016: The Inside Story
Jun-23-16 04:55PM  As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs
Jun-21-16 10:30AM  Expect More Election Year Volatility For Biotech ETFs
Jun-07-16 12:33AM  Biotech Bounce: Sizzle Or Fizzle?
Jun-06-16 08:00AM  A Catalyst for Biotech ETFs
Jun-03-16 08:00AM  Trying to Believe in Biotech ETFs
Jun-01-16 08:30AM  Finally A Biotech ETF Bounce?
May-27-16 11:37AM  Government Study: Cellphone Radiation Linked To Cancer
May-26-16 05:30AM  10 Best Performing ETFs Year To Date
May-17-16 11:40AM  Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
May-16-16 10:07AM  Deals Boost Niche, Equal-Weighted ETFs at Barrons.com
08:00AM  Resisting the Temptation of Biotech ETFs
May-13-16 06:07PM  Medivation Is for Sale: How Much Should It Get?
06:06PM  How Can Regeneron Pharmaceuticals Boost Revenue from Praluent?
04:48PM  What Lies Ahead for Biotech ETFs?
May-04-16 09:07AM  A Look at Vertexs Cystic Fibrosis Patient Opportunity
May-03-16 05:49PM  Understanding Alexions Share Price Performance since Its Previous Earnings
May-02-16 03:22PM  Biotech ETFs Sink on Mixed Q1 Results
12:49PM  Hit The Lab With These 17 Biotech ETFs
Apr-30-16 01:05AM  Seattle Genetics Valuation: How Does It Compare? Market Realist
12:01AM  [$$] Apple's Selloff Has a Mixed Effect on ETFs at Barrons.com
Apr-28-16 09:08AM  Whats Regeneron Expecting for Revenue in 1Q16? Market Realist
Apr-18-16 11:07AM  Could Xtandis Use for Breast Cancer Be a Valuation Driver?
Apr-07-16 11:30AM  Biotech Regain Health: ETFs to Prescribe
Apr-06-16 10:07AM  Neurocrine Biosciences Valbenazine Launch: What You Need to Know +5.92%
Mar-31-16 12:21PM  Q1 ETF Asset Report: Safe Havens Pop; Currency Hedged Drop
07:27AM  Focus 5 ETF Makes Another Change
Mar-21-16 08:12AM  Focus 5 ETF Gets A Dynamic Counterpart
Mar-07-16 08:07AM  BioMarins Naglazyme Sales Dipped by 31.3% Last Year
Mar-05-16 10:40AM  Why Raptor Pharmaceutical Corp. Plunged 13.1% in February at Motley Fool
Mar-02-16 12:39PM  February ETF Asset Update: Safe Assets Gain; Stocks Shed
Feb-29-16 09:43PM  Is The Biotech Bear Market Over? at Forbes
Feb-23-16 10:05PM  Understanding Regenerons Premium Valuation
Feb-13-16 04:30PM  Last Week's Best Healthcare ETF at Motley Fool
Feb-12-16 06:00PM  Regeneron Pharmaceuticals Major Revenue Sources in 4Q15
Feb-09-16 08:14PM  Transportation, Jets ETFs Speed Up As Oil Falls Below $28
03:59PM  Vertex Pharmaceuticals Inc. Dropped 26% in January -- Here's Why at Motley Fool
01:48PM  Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Feb-08-16 01:32PM  Popular ETF Of ETFs Gets Defensive After Market Slide
03:26AM  The FV Shuffle: Giant ETF Trades? No Problem!
Feb-05-16 07:15PM  Big Dorsey Wright ETF Gets Defensive After Sharp Drop at Barrons.com
12:39PM  Niche Tech ETFs Crushed Under Massive Selloff at Barrons.com
Feb-03-16 10:08AM  How Much Does Biogen Spend on Research and Development?
Jan-31-16 02:46PM  Tracking The Biotech Bubble's Bust at Forbes
Jan-27-16 12:31PM  Will Regenerons Earnings Continue to Impress Investors?
Jan-26-16 10:07AM  Orkambi: Recent Addition to the Vertex Portfolio
Jan-22-16 11:07AM  Pomalyst and Abraxane Revenues Are Critical for Celgene
Jan-18-16 08:59AM  Bloodied Biotech Stocks Had It Coming, But Check Out This Chart at Forbes
Jan-15-16 10:55AM  (XBI, FBT, IBB) 3 Bond ETFs in the Biotech Sector at Investopedia
Jan-12-16 09:29AM  Opening Bell, January 12, 2016
09:15AM  Today's Bell Ringer, January 12, 2016
Jan-11-16 12:21PM  The Top 5 Biotechnology ETFs for 2016 (XBI, IBB) at Investopedia
Jan-08-16 05:55PM  What Lies Ahead for Biotech ETFs in 2016?
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.